FI95258B - The method prepares therapeutically active substituted dihydropyrrolizine compounds - Google Patents

Description

. ororq 2_ ^ V- · '<1. w C 1

Method for the preparation of therapeutically active substituted dihydropyrrolizine compounds - Förfarande för framställning av terapeutiskt verkande substituerade dihydropyrrolizinförenin-gar

The invention relates to a process for the preparation of therapeutically active substituted dihydropyrrolizine compounds of general formula I.

; <Af ·

R 5 wherein in each case two of R 3, R 4 and R 5 independently of one another denote a phenyl or naphthyl group which is optionally substituted by one or two of the following: halogen, nitro, C 1 -C 4 alkoxy, hydroxy, C 1 -C 4 alkyl or phenoxy group, but do not simultaneously mean an unsubstituted phenyl group, and the third of the groups R 3, R 4 and R 5 is -CO 2 H, -COSC 1 -C 4 alkyl or AX, where A represents a straight-chain or branched C 1 -C 6 alkylene group which may optionally be an oxygen heteroatom or a carbonyl group or a C 2 -C 8 alkenyl group and X is -CO 2 H or -SO 3 H, and R 6 and R 7 are independently hydrogen or a C 1 -C 4 alkyl group, and pharmaceutically acceptable salts and esters thereof.

. It is known that arachidonic acid is metabolized by two different pathways. By the cyclooxygenase pathway, arachidonic acid is metabolized by the enzyme cyclooxygenase to prostaglanins. By the lipoxygenase pathway, arachidonic acid is metabolised by lipoxygenase to so-called leukotrienes.

2 9525S

Prostaglandins play a role in the development of inflammation, fever, and pain, while leukotrienes play an important role in the development of dyspnea, inflammation, and hypersensitivity conditions.

Non-steroidal antipyretics such as arylacetic acid, 2-arylpropionic acid and anthranilic acid derivatives are often used to control these symptoms. These derivatives inhibit cyclooxidase and thus prevent the formation of prostaglandin from arachidonic acid. However, the use of such derivatives is not harmless due to side effects. Lipoxygenase inhibitors are not commercially available.

Surprisingly, it has now been found that certain substituted pyrrole compounds are effective cyclooxygenase and / or lipoxygenase inhibitors and are therefore useful in the prevention of allergic diseases and in the treatment of rheumatic diseases.

The pharmaceutically acceptable salts of the compounds of formula I may in this case be acid addition or base addition salts. Acid addition salts include inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid, or organic acids such as tartaric acid, lactic acid, citric acid, malic acid, mandelic acid, ascorbic acid, maleic acid, fumaric acid, gluconic acid and its gluconic acid.

Base addition salts include salts of the compounds of formula I with inorganic bases such as sodium or potassium hydroxide or organic bases such as mono-, di- or triethanolamine.

. . Esters of the compounds of the formula I include in particular physiologically easily hydrolysable esters, for example alkyl, pivaloyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl esters.

The phrase "alkyl, alkoxy, etc." comprises straight-chain and branched alkyl groups such as methyl, ethyl, n- and i-propyl, n-, i- or butyl, etc.

95258

The term "halogen atom" includes a fluorine, chlorine, bromine or iodine atom, and in particular a fluorine or chlorine atom.

Preferred are compounds of formula I wherein two of R 3, R 4 and R 5 are phenyl optionally substituted with one or two of the following groups; halogen, especially fluorine or chlorine, a C 2 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy and phenoxy group, and the third group is AX, wherein A represents a C 1 -C 8 alkylene group or a C 1 -C 8 alkenylene group and X is C02H.

AX is in particular C2-C6-alkylene-CO2H or C2-C6-alkenylene-CO2H or and particularly preferably (CH2) 2CO2H, CH2CO2H or CH = CHCO2H.

R6 and R7 are preferably in the 2-position of the pyrrolizine backbone and in particular both represent a hydrogen atom or a methyl group.

Particularly preferred embodiments are the compounds of the formulas:

AX R

AX

V

Γ · - ίΛ Γ Ο S * ~ · / (Λ ks <u ~ ν / ^ 4 wherein R6 and R7 represent a hydrogen atom or a C1-C4-alkyl group and R3 and R4 represent a phenyl group which is optionally substituted by one or two residues) , selected from the group consisting of a halogen atom, a nitro, C 1 -C 4 alkoxy, C 1 -C 4 alkyl or phenoxy group, AX has the meanings given above in connection with formula I.

The substituents on the phenyl group are then in particular selected from a halogen atom, in particular a fluorine or chlorine atom, a C1-C4-alkyl, C1-C4-alkoxy or a phenoxy group. The substituents are primarily in the m and / or p position.

A is then in particular a C 1 -C 6 alkylene group or a C 1 -C 6 alkenylene group, in particular a C 2 -C 6 alkylene or C 1 -C 8 alkenylene group, X is preferably CO 2 H.

Particularly preferred compounds are: (2,2-dimethyl-6,7-diphenyl-2,3-dihydro-1H-pyrrolizin-5-yl) acetic acid and 3- (2,2-dimethyl-6- (4-phenoxyphenyl)) -7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl) propionic acid.

The synthesis of the compounds of formula I, takes place in the first step according to the following formula (1): R7 r3 \ CH2Rc4

* * - “-? -E

, CH2 -> <^ 0 X = Cl. ΒΓ R6 n = 1 - 3 R3 4

II

This synthetic step and the following are illustrated as examples of diphenyl-substituted pyrrolizine compounds. The first reaction step is illustrated in more detail in the following reaction scheme:

Qiror.q - / Ji-vO 5

Reaction Scheme (1): f Ethanol, / V. \ J-S ^ rr \ -r \ / U Ethanol, / -

NaHCOa, ^ / <Il + ° = c HgO ^ 0 "^ 15% \ 6 6 CH Ethanol, OS 3 O, k NaHCOi N + ΜΓ> - ^ °, Δ> OO—

Cl · -CX 20-30% // ό "6 The reaction conditions for these reactions are known, they are described in Chemiker-Zeitung, 110 (1986), No. 7/8, pages 267, 271 and Arch. Pharm. 321, 159-162 (1988).

6 9! J ν '^ S \ J \ J V'

In the second step, the formyl or methyl group is introduced into the pyrrole ring and further reacted into the corresponding acetic acid or ethanol derivatives according to the following reaction scheme (2):

Reaction scheme (2): __ pocb.dmf, / = \ / Hr \ / \ benzene, Δ / _ / \

--- VN

CHO

uaih4 <thf / ^ r ^ K / = \ ch2oh O ^ ch0 Q ^ Hs0h

CHO CH2OH

OK} tl 7 cn;? C; p S i- K- <

J N2CHCOOC2H5. / ^ _ 7 / V

/ "r ^ A / \ Cu® toluene, A / Hr \ _ / λ

VnJAj- "VN ^ fAi CHj-COOC ^ Hs UAIH <. THF / ^ X ^ \ / ^ λ ^ VN> iAi

CH 2 CH 2 OH

<ch2-cooc2h5 <f j; A— ch2-ch2oh \ ^ N ^ y \ ___ N- ^ y

CH2-COOC2H5 CH2-CH2OH

8 C F O r; o

'-ϊ · - V,' C

These reactions and reaction conditions are known and are described in Chemiker-Zeitung, 110 (1986), No. 7/8, 267-271 and Arch. Pharm. 321, 159-162 (1988).

The preparation of the corresponding formic acid, propionic acid and acrylic acid derivatives is described in Arch. Pharm. 321, 545-549. It proceeds according to the following reaction schemes (3) and (4).

«F 11

Reaction scheme Q): c γ: ογρ g ^ w ^ j CICOSC2H51 1 0 / y ^ \ Aia ^ cHzCia Jj SC2H5 KOH. f ethanol, Δ / - "V-nJ ^ 00014 XC ^ SC2H5 cooh 10

Reaction Scheme (4): r rr 'γ »; ✓ Ο ί. V, · V-1 wwig- C-COOC2H5 koh, (ΓΛ-CHO React0 ethanol A „jT 1 HVROj.

^ / c-cooh ethanol

sJO- ^ —2 ^ - Q ^ y <CH2) 2-COOH

cooc2h5 cooh // Η ^ Ό \ li -— Cv

C-H XC "H (CH2) rCOOH

i: 0 ^ 0 0 ^ -0 G ^ O

11 it · ”Γ w« L-. V.,

The corresponding butyric acid derivatives are prepared according to the following reaction scheme (5). It first prepares 4-oxobutyric acids using succinic anhydride by Friedel-Crafts acylation (E. Berlina, Org. Reakt. 1949, 5, 229-289), which are reduced according to the Huang-Minlon variant of the Wolff-Kishner reduction with hydrazine / KOH. diethylene glycol. The reaction conditions are known to the person skilled in the art.

12

Reaction scheme (5):

P525G

/ = \ 0 ^ 0 / = \ A1Cl3 <CHzCJj N //

0 ^ X (CH 2) 2 COOH

H 2 N-NH 2. NaOH, y diethylene \ N /} glycol, A \

(CH 2) RCOOH

V ^ nT / Ct <yV (CH2) 3-COOH

^ (CH2) 2-COOH ^ "Sf i; Os

XC- (CH2) 2-COOH (CH2) 3-COOH

13 S5 · ^ · O t.

Valeric acid derivatives can be prepared in a uniform manner to the corresponding butyric acid derivatives via 5-oxovaleric acid derivatives obtainable by Friedel-Crafts acylation using glutaric anhydride from pyrrolizine base compounds. In a similar manner, caproic acid derivatives are obtained by acylation of diphenylpyrrolizines according to Friedel-Crafts with methyl 5- (chloroformyl valerate / AlCl 3) and saponification of the obtained 6-oxocaproic acid methyl ester derivatives followed by reduction of the oxovaleric acids KOH: hydrazine

The phenyl-substituted compounds are prepared in a uniform manner. Hydroxyl-substituted compounds are prepared by ether cleavage with BBr3 from the corresponding alkoxy derivatives (Tetrahedron, 1968, 24, 2289-2292).

The compounds of the invention have been shown to be potent cyclooxygenase and / or lipoxygenase inhibitors. Therefore, they are useful in the treatment of diseases of rheumatic forms and in the prevention of allergic diseases. The compounds of the invention are thus effective anti-inflammatory, analgesic, antipyretic, anti-hypersensitivity and bronchodilator agents and are useful in the prevention of thrombosis and shock in hypersensitivity reactions, in the treatment of sudden or chronic allergic or non-allergic rash.

The compounds of the invention may be administered as therapeutic or prurituss, either alone or in admixture with other therapeutic agents. They may be administered alone, but will generally be administered in the form of pharmaceutical preparations, which means in admixture of the active ingredients with suitable pharmaceutical carriers or diluents. The compounds may be administered orally or parenterally, however, they are preferably administered in oral dosage forms.

The nature of the pharmaceutical preparation and the pharmaceutical carrier or diluent will depend on the desired route of administration. For example, oral preparations may be in the form of tablets or capsules and may contain conventional excipients (e.g. syrup, acacia, gelatin, sorbitol, tragacanth or polyvinylpyrrolidone), excipients (e.g. lactose, sugar, corn starch, calcium phosphate, sorbitol) or glidants (e.g. magnesium stearate, talc, polyethylene glycol or silica), disintegrants (e.g. starch) or wetting agents (e.g. sodium lauryl sulphate). Liquid preparations for oral administration may be in the form of aqueous or oily suspensions, solutions, emulsions, syrup bases or sprays, etc., or may be in the form of a dry powder to be mixed with water or other suitable carrier. Such liquid preparations may contain conventional additives, for example, suspending agents, flavoring agents, diluents or emulsifying agents. For parenteral administration, solutions or suspensions in conventional carriers may be employed.

The compounds or medicaments of the invention may be administered to a mammal (human or animal) in dosages of about 0.5 mg to about 10 mg per kilogram of body weight per day. They may be administered in single doses or in multiple doses.

The efficacy of the compounds of the invention can be determined. Using 5-lipoxygenase or cyclooxygenase contraception.

The studies were performed as follows:

Experimental Arrangement for Determining 5-Lipoxygenase Inhibition Bovine granule cells, which, like human granule cells, are capable of forming leukotriene C 59 ^ 8 15 - c e, were selected as the source of 5-lipoxygenase. Excitation by calcium ionophore (see Biochem. Biocphys.

Acta 1984, 795, 499-503) is mainly derived from LTC4 (Leu-cotriene C4) from endogenous arachidonic acid. Separation of granule cells and performance of the enzyme reaction is performed using known methods (see Biochem., Biophys. Acta 1984. 795, 499-503). The EDTA-protected water is first centrifuged for this purpose and the platelet-rich upper layer is removed. After the red cells are dissolved with water, the lymphocytes and monocytes are separated from the granule cells using a Ficoll gradient. Grain cells are adjusted to a specific cell number. The enzyme reaction is then initiated in the presence or absence of the test substances after the addition of Ca 2+ by means of a calcium ionophore. Leukotriene synthesis is stopped after 5 minutes with a mixture of methanol and acetonitrile containing PGB2 as internal standard and NDGA as antioxidant.

The samples are then diluted with water and treated as in J. Chromatogr. 1986. 378, 208-214.

LTB4 is measured at absorption maxima at 270 nm. Arakiic acid metabolites are found almost quantitatively in this study.

Experimental set-up to determine β-oxygenase inhibition In this experimental set-up, the amount of 12-HHT formed from bovine granules after the addition of the calcium ionophore is determined by the amount of 12-hydroxyheptadecatrienoic acid or prostaglandin E2 after UV determination after high-performance liquid chromatography separation. In this case, platelets are recovered from the upper layer formed after centrifugation of bovine blood. The enzyme reaction and the separation of the formed metabolites take place in the same way as in the determination of 5-lipoxygenase inhibition, however, the duration of action has been one minute. The determination of 12-HHT after high performance liquid chromatography is performed at 232 nm.

16 e r: o r, r + '«u ~ W' w

The results obtained when testing the compounds according to the invention are summarized in the following Table 1. The test substances were then used in concentrations of 10 μΜ.

Table 1: Inhibition of 5-lipoxygenase and β-oxyoxenase by pyrrolvin compounds R3 <(10 μΗ) R5 inhibition% lipoxycyclo- R3__R3_Rf_R7 genease oxygenase phenyl m-chloro- (CH2) 2CO2H HH2-phenyl phenyl-p-chloro 98 phenyl phenyl p-tolyl (CH2) 2CO2H HH 92 phenyl p-methoxy- (CH2) 2CO2H HH 91 phenyl phenyl p-phenoxy- (CH2) 2CO2H HH 98 phenyl phenyl α-naphthyl (CH2) 2CO2H HH 94 phenyl p- fluoro- (CH2) 2CO2H CH3 CH3 93 phenyl (3.3 μΜ) phenyl p-tolyl (CH2) 2CO2H CH3 CH3 93 (3.3 μΜ) phenyl p-phenoxy- (CH2) 2CO2H CH3 CH3 98. · phenyl (3 , 3 μΜ) * «

comparison Results

The compounds prepared according to the invention were also compared with known compounds by the methods described above. The results are shown in Table 2, which shows that the C Γ Ο Γ, f '·

7 s O v * · O

the compounds are 3 to 10 times more effective at lower doses than the known compounds.

Table 2

Compounds of formula I.

Inhibition% (concentration, μΜ)

_R ^ _R6 R7_LO_CO

phenyl p-Cl-phenyl CH2-COOH CH3 CH3 100 (1) 70 (1) phenyl p-OCH3-phenyl CH2-COOH CH3 CH3 85 (1) 62 (1) phenyl p-NO2-phenyl CH2-COOH CH3 CH3 92 (3,3) 95 (1) phenyl m-Cl-phenyl CH 2 -COOH CH 3 CH 3 75 (3,3) phenyl o, p-Cl-phenyl CH 2 -COOH CH 3 CH 3 72 (3,3) phenyl m, p- Cl-phenyl CH2-COOH CH3 CH3 74 (3,3) phenyl 2,3,4-Cl-phenyl CH2-COOH CH3 CH3 79 (3,3) phenyl p-Cl-phenyl CH2-COOH HH 85 (3,3) ) 50 (1)

Background Art phenyl phenyl CH2-COOH CH3 CH3 44 (3.3) 82 (1) phenyl phenyl CH2-COOH HH 68 (10) 55 (10) phenyl p-Cl-phenyl CHO HH 14 (10) 71 (10) phenyl p-CH 3 O-phenyl CHO HH 56 (10) 74 (10) phenyl p-Cl-phenyl CH 2 -H HH 19 (10) 51 (10)

The following examples illustrate the invention. All temperature values are uncorrected. IR spectra were taken on KBr compresses unless otherwise indicated. NMR spectra are, unless otherwise indicated: 90 MHz spectra taken in CDCl 3 as tetramethylsilane (TMS) as an internal standard.

The preparation of the novel compounds of the formula I and the preparation and properties of the starting compounds used in the reaction are described in the following publications:

18 15 25G

Arch. Pharm. 312, 896-907 (1979)

Arch. Pharm. 319, 500-505 (1986)

Arch. Pharm. 321, 159-162 (1988)

Arch. Pharm. 321, 545-549 (1988)

Chemiker Zeitung, 110 (1986), 7/8, 267-271

General grade whey for the preparation of 4- (diphenyl-2,3-dihydro-1H-pyrrolizinyl) -4-oxobutyric acid

To a solution of 4 mmol of diphenyl-2,3-dihydro-1H-pyrrolizine and 4 mmol (0.40 g) of succinic anhydride in 16 ml of absolute CH2Cl2 are added portionwise under ice-cooling with stirring over 5 minutes 8, 8 mmol (1.17 g) of AlCl 3. It is then stirred for 45 min. at room temperature. The reaction mixture is then poured into 150 ml of ice water. After addition of 4 ml of 8% H 3 PO 4, the mixture is extracted three times with CHCl 3, the organic phases are dried over Na 2 SO 4 and the solvent is distilled off. The product is separated by column chromatography (silica gel, 1st ether, 2nd ether / THF 1 + 1). The product fractions are evaporated to dryness, the residue is dissolved in a small amount of CHCl3. after addition of n-hexane and re-evaporation, the product precipitates.

General Preparation of 4- (Diphenyl-2,3-dihydro-1H-pyrrolizinyl) butyric acid 0.5 mmol of 4- (diphenyl-2,3-dihydro-1H-pyrrolizinyl) -4-oxobutyric acid are mixed with 10 ml of diethylene glycol. With 50 mmol (2.8 g) KOH and 30 mmol (1.5 g) hydrazine hydrate.

The reaction mixture is heated to reflux for 1 h (bath temperature about 170 ° C). The reflux condenser is then replaced by a distillation bridge; and heating further until the internal temperature has reached about • «210 ° C. This temperature is then maintained for 2 h. After cooling, the reaction mixture is poured into 150 ml of H 2 O, acidified with 8% H 3 PO 4 and extracted three times with ether. The extracts are washed with H 2 O, dried and evaporated to dryness. The product is separated by column chromatography (silica gel, ether / THF 4 + 13).

Il 19 f; Γ, ri r; γ s ί- K.

diisopropyl ether 4J), ether 41a; 11a and ether / n-hexane 4 + 1 41b) and precipitated with n-hexane.

General Preparation of 5- (Diphenyl-2,3-dihydro-1H-pyrrolizinyl) -5-oxovaleric acids 4 mmol of diphenyl-2,3-dihydro-1H-pyrrolizine are reacted in 16 ml of absolute CH2Cl2 with 4 mmol (0, 46 g) glutaric anhydride and with 8.8 mmol (1.17 g) AlCl 3 in accordance with the general procedure for 4- (diphenyl-2,3-dihydro-1H-pyrrolizinyl) -4-oxobutyric acid (see page 222). In contrast, the reaction mixture is poured into ice water immediately after the addition of AlCl3 and the preparation is completed. The product is purified using a silica gel column (silica gel / ether).

General Procedure for the Preparation of 5- (Diphenyl-2,3-dihydro-1H-pyrrolizinyl) -5-valeric Acids 0.5 mmol of 5- (diphenyl-2,3-dihydro-1H-pyrrolizinyl) -5-oxovaleric acids is reacted uniformly with 4- (diphenyl-2,3-dihydro-1H-pyrrolizinyl) -4-oxobutyric acid. The product is separated by column chromatography (silica gel, ether) and precipitated with n-hexane.

General generic slurry for the preparation of 6- (diphenyl-2,3-dihydro-1H-pyrrolizinyl) -6-oxocaproic acid methyl ester

To a solution of 10 mmol of diphenyl 2,3-dihydro-1H-pyrrolizine and 10 mmol (1.78 g) of methyl 5- (chloroformyl) valerate in 50 ml of absolute CH 2 Cl 2 is added under ice-cooling and stirring. Within 5 minutes, 22 mmol (2.93 g) of AlCl 3 were added portionwise. Immediately thereafter, the reaction mixture is poured into 150 ml of ice-cooled 10% NaCl solution.

After addition of 4 ml of 8% H3PO4, the mixture is extracted three times with ether, the organic phases are dried over Na2SO4 and the solvent is distilled off. The product is separated by column chromatography (silica gel, 1. n-hexane / ether 1 + 4 with 4-8, 50a and 50b 95258 or 1. toluene, 2. hexane / ether 1 + 4 with 9). The eluates are first evaporated to a volume of about 100 ml, washed twice with 0.05N NaOH and twice with 10% NaCl solution and finally dried over Na2SO4. The products precipitate on evaporation of the solution or crystallize after distilling off the solvent.

General procedure for the preparation of 6- (diphenyl-2,3-dihydro-1H-pyrrolizinyl) -6-caproic acids

A solution of 1 mmol of 6- (diphenyl-2,3-dihydro-1H-pyrrolidinyl) -6-oxocaproic acid methyl ester in 10 ml of ethanol is heated to boiling. 5 ml of a 10% aqueous KOH solution which had been degassed by boiling are then added dropwise and the mixture is heated for a further 15 minutes. reflux. After cooling, the reaction mixture is poured into 100 ml of 5% NaCl, acidified with 8% H3PO4 and extracted three times with ether. The organic phases are dried over N2SO4 and evaporated to dryness. The residue is reacted with 50 mmol (2.8 g) of KOH and 30 mmol (1.5 g) of hydrazine hydrate in 10 ml of diethylene glycol uniformly with 4- (diphenyl-2,3-dihydro-1H-pyrrolizinyl) - with general instructions for butyric acids and purified by column chromatography using silica gel.

General Preparation of 2- (Diphenyl-2,3-dihydro-1H-pyrrolizinyl) -propionic acid ethyl ester 5 mmol of diphenyl-2,3-dihydro-1H-pyrrolizine dissolved in 4 ml of absolute toluene is reacted with 7.5 mmol; (0.96 g) of 2-diazopropionic acid ethyl ester dissolved in 2 ml of absolute toluene, in accordance with the general procedure for the preparation of diphenyl-2,3-dihydro-1H-pyrrolizinylacetic acid ethyl esters. However, the reaction time is 2 h. Purification is carried out by column chromatography (Al 2 O 3), n-hexane / ether 9 + 1). The product is precipitated with ethanol.

21 C n; o r; r S \ J L ·. p ^. ·

General procedure for the preparation of 2- (diphenyl-2,3-dihydro-1H-pyrrolizinyl) -propionic acid ethyl esters of 1.5 mmol 54 or 0.5 mmol 55a and 55b. dissolved in 12 ml or 9 ml of ethanol are saponified with 8 ml or 2.5 ml of a 10% aqueous solution of KOH in accordance with the general procedure for saponification of diphenyl-2,3-dihydro-1H-pyrrolizinylacetic acid ethyl esters. with work instructions. The time used for saponification is 15 min for 54, 55a for 55a and 60 min. Purification is carried out by column chromatography (silica gel, 1. n-hexane / ether 1 + 1, 2. ether). After evaporation of the eluates to dryness, the products are precipitated with n-hexane.

Preparation 1 5- (1- (5,6-Diphenyl-2,3-dihydro-1H-pyrrolizin-7-yl) ethyl) -2,2-dimethyl-1. 3-dioxane-4,6-dione (59a)

To a solution of 4 mmol (1.04 g) of 3a, 4 mmol (0.58 g) of 2,2 dimethyl-1,3-dioxane-4,6-dione (Meldrum’s acid) and 8 mmol (0.35 g) of ) of freshly distilled acetaldehyde in 40 ml of acetonitrile, is allowed to stand for 24 hours at 30 ° C. After cooling in an ice bath, the precipitated product is filtered off with suction. Yield: 0.44 g (26%)

M.p .: 169 ° C (decomposes) IR: = 1790 (C = OP), 1755 (C = O), 1605 (C = C) cm -1

Swim

Preparation 2 3- (5,6-Diphenyl-2,3-dihydro-1H-pyrrolizin-7-yl) butyric acid. the ester (60a) mmol of preparation 1 is dissolved in a mixture of 5 ml of absolute pyridine and 1.0 ml of absolute ethanol. After the addition of a little copper powder, heat for 3 h at reflux. The copper powder is filtered off with suction and the solvent is distilled off under reduced pressure. The product is separated from the residue by column chromatography (silica gel, n-hexane / CH 2 Cl 2 1 + 2).

Yield: 95 mg (25%) IR: '' max = 1735 (c = °) »16 05 (C = C) cm -1

General procedure for the preparation of 6-aryl-7-phenyl-2,3-dihydro-1H-pyrrolizines or 6-phenyl-7-aryl-2,3-dihydro-1H-pyrrolizines 20 mmol of aromatic-substituted or unsubstituted α-bromoacetophenone , dissolved in 25 ml of CH2Cl2, is mixed with a solution of 20 mmol of unsubstituted or aromatic-substituted 2-benzyl-A1-pyrroline in 50 ml of ethanol and stirred for 24 h at room temperature. 20 ml of saturated NaHCO3 solution are then added and the mixture is stirred for a further 24 h at room temperature. The reaction mixture is poured into 50 ml of 5% NaCl solution and extracted three times with 100 ml of each ether / CH2Cl2 3 + 1. The organic phase is dried over Na 2 SO 4 and finished as described below.

* α-Bromo-3-chloroacetophenone, or-bromo-3,4-dimethoxyacetophenone, o-bromo-3,4-dichloroacetophenone and α-bromo-4-phenoxyacetophenone are not commercially available. They were prepared as follows:

To a solution of 20 mmol of 3-chloroacetophenone, 3,4-dimethoxyacetophenone, 3,4-dichloroacetophenone or 4-phenoxyacetophenone in 15 ml of CH2Cl2 and 10 ml of dioxane are slowly added dropwise a solution of 20 mmol (3.2 g) of bromine in 10 mL of CH 2 Cl 2. 50 ml of CH2Cl2 are then added and the mixture is washed twice carefully with 5% NaHCO3 solution to remove HBr. The organic phase is dried over Na2SO4 and evaporated to dryness. The residue is immediately reacted as described above with 20 mmol of 2-benzyl-Al-pyrroline.

2- (4-chlorobenzyl) -Al-pyrroline 23, .. r · - C. r, [f J ^

W

Preparation in accordance with one with 2-benzyl-Al-pyrroline (J.

Amer. Chem. Soc. 1932, 54, 3971-3976) ** 2- (4-methylbenzyl) -M-pyrroline from 0.15 mol (3.6 g) Mg and 0.15 mol (21.1 g) 4-methylbenzyl chloride Prepare in 150 ml of absolute ether Grignard reagent. After dropwise addition of 0.15 mol (15.5 g) of 4-chlorobutyronitrile dissolved in 100 ml of absolute ether, heat for 2 h. The ether is then distilled off and 200 ml of absolute xylene are added. After further heating at reflux for 2 h, 100 ml of H2O are added to the reaction mixture under ice-cooling and acidified with dilute H3PO4. The aqueous phase is made alkaline under ice-cooling with concentrated NH3, and the precipitate formed is filtered off with suction. The filtrate is extracted three times with 50 ml of CH2Cl2, the precipitate is washed with 100 ml of CH2Cl2 · CH2Cl2 solutions, evaporated to dryness, dried over Na2SO4 and evaporated to dryness. The product is separated from the residual residue by distillation (boiling point 117 ° C in 0.1 torr).

Yield: 3.7 g (14%) of c 12 H 15 N (173.3) IR: vmav = 1640 (C = N), 1605 (C = C) cm -1 ιιίαΛ ** 2- (4-methoxybenzyl) -δ! - pyrroline 3.0 mol (72.9 g) of Mg and 0.15 mol (23.5 g) of 4-methoxybenzyl chloride are prepared in 500 ml of absolute ether 4-methoxybenzylmagnesium chloride, which is reacted with 0.15 mol ( 15.5 g) 4-chlorobutyronitrile and purified by distillation (boiling point 142 ° C in 0.1 torr).

Yield: 2.4 g (8%) of C 12 H 15 N (189.3) IR: v = 1640 (ON), 1610 (C = C) cm -1

General procedure for the preparation of 3- (6-chlorophenyl and 6-nitrophenyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl) propionic acid methyl esters 24 95256 4 mmol of 6-chloro or 6-nitrophenyl-7 -phenyl-2,3-dihydro-1H-pyrrolizine and 6 mmol (0.52 g) of acrylic acid methyl ester are dissolved in 16 ml of absolute dichloroethane. After adding 0.24 ml of the BF3-ethyl ether complex, the mixture is stirred for 1 hour at room temperature, after which the same amounts of acrylic acid methyl ester and the BF3-ethyl ether complex are added after 15 minutes each time. The reaction mixture is then poured into 100 ml of 10% NaCl solution and extracted twice with ether / CH2Cl2 3 + 1. The organic phases are dried over Na2SO4 and evaporated to dryness. The residue is further processed as described below.

General procedure for the preparation of 3- (6-chlorophenyl and 6-nitrophenyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-6-yl) propionic acid methyl esters.

A solution of 1 mmol of the corresponding pyrrolizinylpropionic acid p-methyl ester in 10 ml of ethanol is heated to boiling.

5 ml of a 10% aqueous solution of KOH, previously degassed by boiling, are then added dropwise and the mixture is refluxed for a further 5 minutes. After cooling, the reaction mixture is poured into 100 ml of 5% NaCl solution, acidified with 8% H3PO4 and extracted three times with ether / CH2Cl2 3 + 1. The organic phases are dried over Na 2 SO 4, evaporated to dryness and further treated as described.

General Vilsmeier for the Vilsmeier formulation of aromatic-substituted 6,7-diphenyl-2,3-dihydro-1H-pyrrolizines, 6 mmol of the corresponding pyrrolizine, dissolved in 6 ml of absolute benzene, is reacted with 18 mmol (1.32 g) of absolute DMF and 6 mm of absolute DMF. .92 g) POCl 3 in accordance with the Vilsmeier formulation of diphenyl-2,3-dihydro-1H-pyrrolizines.

Il 25 Γ> Γ “r \ r-s ^ Kj

To prepare aromatic-substituted 6,7-diphenyl-2,3-dihydro-1H-pyrrolizinic acid ethyl esters of 2.5 ramol of the corresponding carbaldehyde, dissolved in 5 ml of absolute CH 2 Cl 2, is reacted with 2.5 ml (1.08 g) of li with ethanol and with a solution of Na ethanolate prepared from 7.5 mmol (0.17 g) of sodium and 3 ml of absolute ethanol, one for the preparation of diphenyl-2,3-dihydro-1H-pyrrolizinylacrylic acid ethyl esters with general procedure.

A common slurry for the saponification of aromatic-substituted 3- (6,7-diphenyl-2,3-dihydro-1H-pyrrolizin-5-yl) -acrylic acid ethyl esters with 1.2 mmol of the corresponding pyrrolizinyl acrylic acid ethyl ester dissolved in 50 ml of ethanol is reacted with 50 ml of ethanol. aqueous solution according to the general procedure for saponification of 3- (diphenyl-2,3-dihydro-1H-pyrrolizin-5-yl) -acrylic acid ethyl esters.

A common solvent for the hydration of aromatic-substituted 3- (6,7-diphenyl-2,3-dihydro-1H-pyrrolizin-5-yl) -acrylic acids is dissolved in 0.9 mmol of the corresponding pyrrolizinylacrylic acid in 30 ml of absolute THF. After the addition of 10 ml of absolute ethanol and the tip of the spatula PtO 2 (alternatively palladium can also be used), hydrogenate in an autoclave for about 4 hours at about 15 bar. In this case, fresh PtO 2 (or palladium) is added several times with a spatula tip. After the reaction is complete (OK: silica gel, THF), the catalyst is filtered off with suction, the solvent is distilled off and the product is isolated.

26 I · 'L .- C (.

General cleavage slurry to cleave acrylic methyl ethers with 0.5 mmol of the corresponding methoxy compound dissolved in 5 mL of absolute CH 2 Cl 2 is added dropwise at 80 ° C to a solution of 0.20 mL of BBr 3 in 3 mL of absolute CH 2 Cl 2. The mixture is given approx.

During 8 h. Warm to room temperature. After adding 30 ml of H 2 O, extract three times with ether. The organic phases are washed twice with saturated NaCl solution, dried over Na2SO4 and finished. The obtained compounds and the physical properties of these compounds are shown in the following Tables 3-10.

In Tables 3, 7, 8 and compounds 16 and 17 in Table 6 and compound 65 in Table 12 is the starting material.

Table 3 R * n pen y Rmet »R» “

B

E.g.

Well. Rmeta ^ ara R, para Sp. ° C IR (C = C) 1 Cl H H 1600

21) H Cl H

! '3 NO 2 H H 117 1605 4 H NO 2 H 132 1595 5 H H Cl 156 1605 ^ Chemiker-Zeitung 1986, 110, 267-271

II

27 C r; o r; c ^ Ji.Ju

Table 4 D 'p part J. ^ Meta (CHjlj-COOCHj

E.g.

Well. ^ eta ^ ara R, para Sp. ° C IR (C = 0) 6 Cl H H 99 1735 7 H Cl H 98 1730 8 N02 H H 1740 9 H N02 H 1740 10 H H Cl 111 1730

Table 5 para / fime ta RP «r *

(CH2) 2-COOH

E.g.

Well. ^ eta Rpara R’para Sp. ° C IR (C = 0) 11 Cl H H 99 1735 12 H Cl H 98 1730 <13 N02 H H 1740 14 H N02 H 1740 15 H H Cl 111 1730 ί Γ - γ; γ 2 8 "" ^ w ^

Table 6

E.g.

Well. R Sp. ° C IR (C = O) 16 H 1605 (C = C) 17 CHO> 84 1650 18 CH = CHCOOC2H5 (E) 122 1715 19 CH = CHCOOH (E) 229 1660 20 (CH2) 2COOH 157 1710

Table 7

B

E.g.

Well. ^ eta ^ ara R'para Sp. ° C IR (C = C) 21 CH3 H H 1605 22 H CH3 H 1605 23 OCH3 H H 1605

'. · 241} H OCH3 H

2 51 'OCH3 OCH3 H

262) H ° -C 6 H 5 H

27 Cl Cl H 119 1605 28 H H CH3 104 1610 29 H H OCH3 1605

II

29 Γ; Γ r 'Γ. f.

Chemiker-Zeitung 1986, 110, 267-271 2) The product is not pure, it is reacted without further purification.

Table 8 R 'P para

CHO

E.g.

Well. ^ leta ^ ara R, para Sp. ° C IR (C = 0) 30 CH 3 H H 128 1645 31 H CH 3 H 142 1645 32 OCH 3 H H 117 1635

331} H OCH3 H

341 ^ OCH3 OCH3 H

35 H ° -C 6 H 5 H 135 1635 36 Cl Cl H 162 1640 37 H H CH 3 102 1645

Chemiker-Zeitung 1986, 110, 267-271

Table 9 R para .Rmela H i COOC2H5

E.g.

30 9ΓΛΓ: 8

W \ J

Well. ^ eta ^ ara R, para Sp. ° C IR (C = 0) 38 CH3 HH 142 1710 39 H CH3 H 158 1710 40 OCH3 HH 119 1710 41 H OCH3 H 164 1705 42 OCH3 0CH3 H 133 1705 43 H 0_C6H5 H 173 1705 44 Cl Cl H 122 1715 45 HH CH3 222 1705

Table 10, R'p «

«V

COOH

• Ex.

4

Well. Rmeta ^ ara R, para Sp. ° C IR (C = 0) 46 CH3 HH 216 1660 47 H CH3 H 221 1680 48 OCH3 HH 205 1670 49 H OCH3 H 216 1675 '· 50 OCH3 OCH3 H 216 1660 51 H ° -C6H5 H 221 1660 52 Cl Cl H 229 1660 53 HH CH3 118 1665 31 r π; o £; c

Table 11 R'p «

(CH2) 2-COOH

E.g.

Well. ^ leta ^ ara R, para Sp. ° C IR (C = 0) 54 CH3 HH 125 1710 55 H CH3 H 122 1710 56 0CH3 HH 111 1710 57 H OCH3 H 73 1710 58 OCH3 OCH3 H 152 1725 59 OH HH 87 1710 60 H OH H 187 1700 61 OH OH H 76 1710 62 H O-CgHg H 178 1705 63 Cl Cl H 144 1710 64 HH CH3 182 1705

Table 12

R

E.g.

32 Ο «··; '> ρ; 2

• S W im \ J O

Well. R kpara Sp. ° C IR (C = O) 65 H Cl 118 1605 (C = C) 66 (CH 2) 2 COOCH Cl 113 1735 67 (CH 2) 2 COOH 3 Cl 207 1710

Example 68 2,2-Dimethyl-6- (4-fluoro) -7-phenyl-2,3-dihydro-1-pyrrolizine (IV) 20 mmol of c * -chloro-4-fluoroacetophenone dissolved in 25 ml of CH2Cl2 are stirred. with a solution of 20 mmol of 2-benzyl-4,4-dimethyl-A1-pyrroline in 25 ml of ethanol and stirred for 24 h at a bath temperature of 70 ° C. 20 ml of saturated NaHCO3 solution are then added and the mixture is stirred for a further 24 h at the same temperature. The reaction mixture is poured into 500 ml of 5% NaCl solution and extracted three times with 100 ml of ether / CH2Cl2 3 + 1 in each case. The organic phases are dried over Na 2 SO 4. The product precipitates after column chromatographic purification (Al 2 O 3, n-hexane / ether 9 + 1) as an oil.

Yield: 3.1 g (51%) of C 21 H 20 FN (305.4) IR: δ max = 1605 (C = C) cm -1 1 H-NMR: δ (ppm) = 1.28 (s, 6H, -CH 3), 2 .78 (s, 2H, Cl), 3.71 (s, 2H, C-3), 6.64 (s, 1H, C-5), 6.75-7.60 (m, 9H, arom. )

Example 69 / 2,2-Dimethyl-6- (4-fluoro) -7-phenyl-2,3-dihydro-1H-pyrrolizine-5-ylcarbaldehyde (6v) 9 mmol lv, dissolved in 9 ml absolute benzene, is reacted with 27 mmol (1.97 g) of absolute DMF and 9 mmol (1.38 g) of POCl 3 in a uniform manner in the 33 or-> Vilsmeier formulation of diphenyl-2,3-dihydro-1H-pyrrolizines. r c;

· / L

with general work instructions. Purification is performed by column chromatography (silica gel, n-hexane / ether 2 + 1). The product precipitates on evaporation of the eluates.

Yield: 0.9 g (30%)

M.p .: 186 ° C C 22 H 20 FNO (333.4) IR: imax = 1645 (C-O), 1610 (C = C) cm -1 1 H-NMR: δ (ppm) = 1.33 (s, 6H, - CH 3), 2.83 (s, 2H, Cl), 4.18 (s, 2H, C-3), 6.90-7.44 (m, 9H, arom.), 9.38 (s, 1H , -CHO)

Example 70 3- (2,2-Dimethyl-6- (4-fluoro) -7-phenyl-2,3-dihydro-1H-pyrrole-sin-5-yl-acrylic acid ethyl ester (34v) 2 mmol 6v, dissolved in 15 ml to absolute CH2Cl2 is reacted with a solution of 2 mmol (0.86 g) of ethoxycarbonylmethyltriphenylphosphonium bromide in 4 ml of absolute ethanol and with a solution of 6 mmol (0.14 g) of sodium and 3 ml of absolute ethanol (Na-ethanolate solution) in accordance with the general procedure for the preparation of diphenyl-2,3-dihydro-1H-pyrrolizinyl-acrylic acid ethyl esters, purified by column chromatography (silica gel, CH2Cl2).

Yield: 0.33 g (41%)

M.p .: 152 ° C C 26 H 26 FNO 2 (403.5) IR: δ max = 1715 (c = °) / 1620 (C = C) cm -1 1H-NMR: b (ppm) = 1.27 (t, 3H, J = 7Hz, -O-CH 2 -CH 3),; 1.33 (s, 6H, CH 3), 2.86 (s, 2H, Cl), 4.00 (s, 2H, C-3), 4.19 (q, 2H, J = 7Hz, -O- CH 2 -CH 3), 5.90 (AB, 1H, J = 16.4 Hz, = CH-CO-), 6.87-7.34 (m, 9H, arom.), 7.48 (AB, 1H, J = 16.4Hz, Pyr-CH =)

Example 71 34 - - [2,2-Dimethyl-6- (4-fluoro) -7-phenyl-2,3-dihydro-1H-pyrrolidine-5- wli) -acrylic acid (35v) 0.6 mmol of 34v dissolved in 30 ml of ethanol is reacted with 6 ml of a 10% aqueous solution of KOH uniformly in diphenyl-2,3-dihydro-1H-pyrrolizinylacrylic acid ethyl. with general work instructions for saponification of esters.

Yield: 0.20 g (89%)

M.p .: 242 ° C

C24H22FNO2 (375.4) C 76.8 H 5.91 N 3.7 calculated C 76.1 H 5.81 N 3.3 observed IR: ε max = 330 ° · 2200 (OH) * 1685, 1670 (C = 0), 1600 (C = C) cm -1 1 H-NMR (d 6 -DMSO): δ (ppm) = 1.27 (s, 6H, -CH 3), 2.84 (s, 2H, Cl), 4.06 (s, 2H, C-3), 5.92 (AB, 1H, J = 16.4 Hz, = CH-CO-), 6.87-7.41 (m, 9H, arom. And Pyr -CH =)

Example 72 3- (2,2-Dimethyl-6- (4-fluoro) -7-phenyl-2,3-dihydro-1H-pyrrolidin-5-yl) -propionic acid (27v) 0.3 mmol of 35v is introduced to react in accordance with the General Procedure for the Hydrogenation of Aromatic-Substituted 3- (6,7-Diphenyl-2,3-Dihydro-1H-pyrrolidin-5-yl) -acrylic Acids. Palladium is used as the catalyst. The product is precipitated with n-hexane.

Yield: 0.08 g (71%)

M.p .: 182 ° C

: C24H24FNO2 (377'5) c 76'4 H 6 <41 N 3'7 calculated C 75.8 H 6.56 N3.3 observed

IR: £ max = 3300'2200 (0H) '1710 (c = 0)' 1605 (c = c) cm-1: L

1 H-NMR: b (ppm) = 1.30 (s, 6H, -CH 3), 2.28-2.58 (m, 2H, -CH 2 -CO-), 2.73-3.03 (m, 2H, Pyr-CH 2 -), 11 C -> RC '35 2.81 (s, 2H, Cl), 3.68 (s, 2H, C-3), 6.76-7.28 (m, 9H, arom.)

Example 73 2,2-Dimethyl-6- (4-phenoxyphenyl) -7-phenyl-2,3-dihydro-1H-pyrrolizine (Iw) 20 mmol of 2-benzyl-4,4-dimethyl-A1-pyrrolidine lb3 are reacted with 20 mmol. with α-bromo-4-chloroacetophenone in 50 ml of ethanol in accordance with the general procedure for the preparation of 6-aryl-7-phenyl-2,3-dihydro-1H-pyrrolizines.

Purification is by column chromatography (Al 2 O 3, n-hexane / ether 9 + 1). After evaporation of the eluates, lw remains as an oil.

Yield: 2.7 g (36%) C 27 H 25 NO <379.5) IR: imax = 1605 3a 1595 (C = C) C 1 H 1 NMR: δ (ppm) = 1.28 (s, 6H, - CH 3), 2.78 (s, 2H, Cl), 3.71 (s, 2H, C-3), 6.65 (s, 1H, C-5), 6.78-7.57 (m, 14H, arom.)

Example 74 2,2-Dimethyl-6- (4-phenoxyphenyl) -7-phenyl-2,3-dihydro-1H-pyrrolidin-5-ylcarbaldehyde (6w) 6 mmol lw, dissolved in 6 ml of absolute benzene , is reacted with 18 mmol (1.32 g) of absolute DMF and 6 mmol of POCl 3 in accordance with the general procedure for the Vilsmeier formulation of diphenyl-2,3-dihydro-1H-pyrrolizines. Purification is carried out by column chromatography (silica gel, CH2Cl2). The product is precipitated with ethanol.

Yield: 0.94 g (38%)

Sp. : 139 ° C

C28H25NO2 <407'5) IR: £ max = 1645 (C = 0) '1605 3a 1590 (C = C) cm-1 36 P r V .. <' 'f'. · · * V V v.

1 H-NMR: δ (ppm) = 1.30 (s, 6H, -CH 3), 2.81 (s, 2H, Cl), 4.17 (s, 2H, C-3), 6.84-7 .47 (m, 14H, arom.), 9.40 (s, 1H, --CHO)

Example 75 3- (2,2-Dimethyl-6- (4-phenoxy-phenyl) -7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-acrylic acid ethyl ester (34w) 2 mmol of 6w, dissolved in 15 ml of absolute CH2Cl2 is reacted with a solution of 2 mmol (0.86 g) of ethoxycarbonylmethyltriphenylphosphonium bromide in 4 ml of absolute ethanol and with a solution of Na ethanolate prepared from 6 mmol (0.14 g) of sodium and 3 ml of absolute ethanol, in accordance with the general procedure for the preparation of diphenyl-2,3-dihydro-1H-pyrrolizinyl-acrylic acid ethyl esters Purification by column chromatography (silica gel, CH2Cl2) The product remains as a foam after evaporation of the eluates.

Yield: 0.33 g (35%)

Sp. : from 69 ° C

C 32 H 31 NO 3 (477-6> IR: δ max = 1705 (c = O> 1610 (C = C)) 1 H-NMR: δ (ppm) = 1.28 (t, 3H, J = 7Hz, - O-CH 2 -CH 3), 1.33 (s, 6H, CH 3), 2.86 (s, 2H, Cl), 4.00 (s, 2H, C-3), 4.19 (q, 2H, J = 7Hz, -O-CH 2 -CH 3), 5.92 (AB, 1H, J = 16Hz, = CH-CO-), 6.83-7.44 (m, 14H, arom.), 7.56 (AB, 1H, J = 16Hz, Pyr-CH =)

Example 76 3- (2,2-Dimethyl-6- (4-phenoxyphenyl) -7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl) -propionic acid (35v) 0.6 mmol 34w: , dissolved in 30 ml of ethanol, is reacted with 6 ml of a 10% aqueous solution of KOH in diphenyl-37 Ο «\ '' Γ Γ S \ JL ·. With the general procedure for saponification of L '2,3-dihydro-1H-pyrrolizin-5-yl) -acrylic acid ethyl esters.

Yield: 0.23 g (85%)

M.p .: 198 ° C

C30H27NO3 <449'5) c 80.2 H 6'05 N 2> 1 calculated C 79.9 H 6.07 N2.7 observed IR: ξ = 3300-2200 (OH), 1675 (C = 0), 1590 (C = C) cm-1 1 H-NMR (d 6 -DMSO): δ (ppm) = 1.27 (s, 6H, -CH 3), 2.83 (s, 2H, Cl), 4.06 (s , 2H, C-3), 5.92 (AB, 1H, J = 16.2 Hz, = CH-CO-), 6.86-7.57 (m, 15H, arom. And Pyr-CH =)

Example 77 3- (2,2-Dimethyl-6- (4-phenoxyphenyl) -7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl) -propionic acid (27w) 0.3 mmol 35w reacted in accordance with the General Procedure for the Hydrogenation of Aromatically Substituted 3- (6,7-Diphenyl-2,3-Dihydro-1H-pyrrolidin-5-yl) -acrylic Acids. Palladium is used as the catalyst. The product is precipitated with n-hexane.

Yield: 0.10 g (74%)

Sp. : 149 ° C

C 30 H 29 NO 3 (451.6) C 79.8 H 6.47 N 3.1 calculated C 79.5 H 6.61 N 2.7 observed IR: ε max = 3300 "2400 (° H) '1710 (C = 0 ), 1605-1595 (C = C) cm -1 1 H-NMR (d 6 -DMSO): δ (ppm) = 1.29 (s, 6H, -CH 3), 2.34-2.63 (m, 2H , -CH 2 -CO-), 2.77-3.06 (m, 2H, Pyr-CH 2 -), 2.83 (s, 2H, Cl), 3.69 (s, 2H, C-3), 6.85-7.47 (m, 14H, arom.) F .... r; rv 38

Example 78 2- (2,2-Dimethyl-6- (4-phenoxy-phenyl) -7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl) -propionic acid ethyl ester (54a) 2.5 mmol 6- (4-phenoxy-phenyl) -7 -phenyl-2,3-dihydro-1H-pyrrolizine lw, dissolved in 3 ml of absolute toluene, is reacted with 4 mmol (0.51 g) of 2-diazopropionic acid ethyl ester, dissolved in 3 ml of absolute toluene, uniformly with the general procedure for the preparation of diphenyl-2,3-dihydro-1H-pyrrolizinylacetic acid ethyl esters.

Separation is performed by column chromatography (Al 2 O 3, n-hexane / ether 9 + 1). The oily product remaining after evaporation to dryness is not pure (0.45 g). It is further reacted without further purification.

Example 79 2- (2,2-Dimethyl-6- (4-phenoxyphenyl) -7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl) -propionic acid (56a)

The crude 54a (0.45 g) dissolved in 10 ml of ethanol is reacted with 5 ml of a 10% aqueous KOH solution uniformly saponified with diphenyl-2,3-dihydro-1H-pyrrolizinyl-acetic acid ethyl esters. with general work instructions. The saponification time is 90 minutes. Purification is performed by column chromatography (silica gel, diisopropyl ether).

Yield: 90 mg M.p .: 186 ° C C 30 H 29 NO 3 (451.6) IR:? Max = 3300-2400 (0H) '1710 (C = O)' 1605-1595 (C = C) cm -1 1H-NMR ( dg-DMSO): δ (ppm) = 1.23 (s, 3H, -CH3), 1.32 (s, 3H, -CH3), 1.48 (d, 3H, J = 7Hz, CH3-CH < ), 2.72, 291 (AB, 2H, J = 15.5Hz, Cl), 3.81 (s, 2H, C-3), 3.96 (q, 1H, J = 7Hz, -CH <) , 6.81-7.50 (m, 10H, arom.)

Claims (4)

A process for the preparation of therapeutically-substituted dihydropyrrolizine compounds of the general formula I R5 wherein always two of the groups R , a nitro, C1-C4 alkoxy, hydroxy, C1-C4 alkyl or phenoxy group, but does not simultaneously refer to an unsubstituted phenyl group, and the third groups R3, R4 and R5 are -CO2H, -COSC2 -C 3 -alkyl or AX, where A refers to a straight-chain or branched C R7 is independently hydrogen or a -C4 alkyl group, and their pharmaceutically acceptable salts and esters, characterized in that A) a compound of the general formula II: R 'yy II where R6 and R7 are independently hydrogen or a C ^-C ^ alkyl group, about tts with a compound of the general formula III: 5 ^ 91-S 43. C-R5 - CH - C - R4 I II (m) X 0 where X is Cl or Br and wherein in these formulas two of groups R3, R4 and R5 refer to the above and the third of groups R3, R 4 and R 5 are a hydrogen atom to give a compound of the general formula IV: JDÖ - R 5 wherein the groups R 3 - R 7 are as defined above, and B terg group, carbaldehyde group or acyl group, and this when needed is converted by reaction by ester digestion, Witting reaction, hydrogenation or a combination thereof, into a group corresponding to the desired meaning of the groups R3, R4 and R5. The process of claim 1 for the preparation of a compound of formula I, wherein two of the groups R3, R4 and R5 are phenyl group which may be substituted by one or two of the following (but not simultaneously substituted by unsubstituted phenyl): halogen, especially a fluorine or chlorine atom, a C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, phenoxy or nitro group, and the third group refers to AX where A is a C > V ν ρ: ρ SV / fc- Vy V. C 2 -C 8 alkylene group, and X is COOH, characterized in that the corresponding starting materials are used. 3. A process according to claim 1 for the preparation of a compound of formula (Ia) R3 R7 ΛτΛ X X)) - r <Ia / \ // R1 2 ly AX wherein R2 and R3 are a hydrogen atom or a C1-C4 alkyl group, R 3 and R 4 are independently a phenyl group which may be substituted by a halogen atom but may not simultaneously refer to an unsubstituted phenyl group, A is a C 1 -C 6 alkylene group, and X is COOH, characterized in that the corresponding starting materials are used. . A process according to claim 3 for the preparation of a compound of formula Ia, wherein R3 and R4 are independently phenyl group or p-chlorophenyl group, but may not simultaneously refer to an unsubstituted phenyl group, and AX is CH 2 COOH, starting materials are used. A process according to claim 4 for the preparation of a compound of formula Ia, wherein R 2 and R 3 are a C 1 -C 4 alkyl group, in particular a methyl group, characterized in that 3 'corresponding starting materials are used.